Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635–48.

Article  CAS  PubMed  Google Scholar 

Wang HB, Liao XF, Zhang J. Clinicopathological factors associated with HER2-positive gastric cancer: a meta-analysis. Medicine (Baltimore). 2017;96(44):e8437.

Article  CAS  PubMed  Google Scholar 

Zhu Y, et al. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188549.

Article  CAS  PubMed  Google Scholar 

Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.

Article  PubMed  PubMed Central  Google Scholar 

Creemers A, et al. The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget. 2018;9(42):26787–99.

Article  PubMed  PubMed Central  Google Scholar 

Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

Article  CAS  PubMed  Google Scholar 

Shiraishi K, et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. 2013;16(4):571–80.

Article  CAS  PubMed  Google Scholar 

Varchetta S, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67(24):11991–9.

Article  CAS  PubMed  Google Scholar 

Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40.

Article  CAS  PubMed  Google Scholar 

Vivier E, et al. Natural killer cell therapies. Nature. 2024;626(8000):727–36.

Article  CAS  PubMed  Google Scholar 

Zahavi D, et al. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther. 2018;1(1):7–12.

CAS  PubMed  PubMed Central  Google Scholar 

Casey E, et al. A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. 2018;32(2):547–9.

Article  CAS  PubMed  Google Scholar 

Clynes RA, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–6.

Article  CAS  PubMed  Google Scholar 

Dixon KJ, Wu J, Walcheck B. Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells. Cancers (Basel), 2021;13(2).

Li Z, et al. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer. Chin J Cancer Res. 2024;36(3):306–21.

Article  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033–41.

Article  CAS  PubMed  Google Scholar 

Yun C, et al. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. Mol Carcinog. 2015;54(12):1700–9.

Article  PubMed  Google Scholar 

Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.

Article  CAS  PubMed  Google Scholar 

Arora J, et al. T cell help in the tumor microenvironment enhances rituximab-mediated NK cell ADCC. Blood. 2024;143(18):1816–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, et al. T cells, particularly activated CD4(+) cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. Cancer Immunol Immunother. 2022;71(2):237–49.

Article  CAS  PubMed  Google Scholar 

Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48(2):202–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371–81.

Article  CAS  PubMed  Google Scholar 

English D, Andersen BR. Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods. 1974;5(3):249–52.

Article  CAS  PubMed  Google Scholar 

Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008;17(10):1553–8.

Article  CAS  PubMed  Google Scholar 

Hellmann MD, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648–59.

Article  CAS  PubMed  Google Scholar 

Raeber ME, Sahin D, Boyman O. Interleukin-2-based therapies in cancer. Sci Transl Med. 2022;14(670):eabo5409.

Article  CAS  PubMed  Google Scholar 

Pang MJ, et al. Gastric organoids: progress and remaining challenges. Cell Mol Gastroenterol Hepatol. 2022;13(1):19–33.

Article  CAS  PubMed  Google Scholar 

Allen GM, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba1624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derakhshani A, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142–56.

Article  CAS  PubMed  Google Scholar 

Bordron A, et al. Complement system: a neglected pathway in immunotherapy. Clin Rev Allergy Immunol. 2020;58(2):155–71.

Article  PubMed  Google Scholar 

Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.

Article  CAS